



DLA Piper assists Initiator Pharma A/S with list change from Spotlight Stock Market to Nasdaq First North Growth Market Sweden



Lars Hagbard Grønkjær
Partner



Rasmus Schou Pedersen
Advokatfuldmægtig

DLA Piper has assisted Initiator Pharma A/S with a listing change from Spotlight Stock Market to Nasdaq First North Growth Market Sweden.

Initiator Pharma A/S was advised in relation to Danish law by DLA Piper Denmark with a team of Lars Hagbard Grønkjær and Rasmus Schou Pedersen. This team also coordinated advice to Initiator Pharma A/S in relation to certain aspects of Swedish law from our DLA Piper colleagues in Sweden.

Read more about the listing change [here](#).

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition.

